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A computer model for the Dynamics of the Glucose-Insulin-Glucagon
System has been developed for a 17.5 kg canine using the Continuous
Systems Modeling Progam (CSMP) for the 360 Computer System. The
major body components controlling the glucose dynamics (liver, pan-
creas, body muscle, blood flow, and body fluid compartments) have
been modeled in terms of either their production, absorption, or
transport of glucose, and the concentration levels of both the
hormones and substrates perfusing the body component. A set of
mneumonics has also been developed to label the hundreds of constant
and variable terms required to describe a complex system of this
magnitude. The dynamic characteristic of the liver's glycogen storage
capability has also been modeled in terms of stored glycogen and the
blood plasma concentration levels of both glucose and insulin perfus-
ing the liver.
Once the Glucose-Insulin-Glucagon System had been modeled, it
was first tested under basal conditions with three different levels
of glycogen stored in the liver to check the dynamics of the liver
glycogen storage. As expected, when the stored glycogen was below
the equilibrium level, blood glucose was converted to liver glycogen,
and when the stored level was greater, glycogen was converted back
to glucose and returned to the blood.
The Glucose-Insulin-Glucagon System model was then tested with
an almost instantaneous glucose load of 8.75 grams of glucose, elevat-
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ing the glucose concentration level to approximately 3.5 mg of glucose
per ml of blood plasma. This high glucose concentration level returned
exponentially over the next 120 minutes to the basal concentration
level of 100 mg/100 ml, agreeing generally with in vivo test data.
The Glucose-Insulin-Glucagon System model was then tested by
injecting insulin into the model at different rates over an extended
period of time and observing the rate at which the glucose concentra-
tion fell, its final level, and the rate at which the glucose concentra-
tion level returned to the basal concentration level once the insulin
load had been removed. Here again, there was generally good agreement
with in vivo test data, not only for the glucose concentration dynamics
but also for the rate at which glucose was produced by the liver during
the period when insulin was being injected into the model.
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Glucose is the primary energy source for the central nervous
system (CNS), the principal component of which is the brain. An
adequate and stable supply of glucose must be maintained by the body
to keep the brain and all the body functions controlled by the CNS
operating properly. Should the blood level fall below approximately
50 mg of glucose per 100 ml of blood (50 mg/100 ml) (30), a hypo-
glycemic condition results and many of the critical body functions
are impaired. There is the possibility of convulsions, coma, and
even death. When the body is unable to maintain the glucose concen-
tration level below 150 mg/100 ml (29), the disease known as diabetes
is indicated. Again, the disease finally affects the central nervous
system with death resulting if not treated.
To maintain the blood glucose concentration at its basal level
of approximately 100 mg/100 ml (16, 27) for the many varying condi-
tions of stress, exercise, and food ingestion, the body provides many
complex systems to control both the metabolism and synthesizing of
glucose.
A model of the dynamics of the Glucose-Insulin-Glucagon System
would be very beneficial for education, diagnostic, and research
purposes. The many different effects that hormones and gluconeogenic
substrates have upon the dynamics of the glucose concentration of the
blood, the glycogen storage of the liver and the body muscle, and the
ix
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concentration levels of the various gluconeogenic substrates that are
used by the liver to synthesize glucose can be studied without having
to sacrifice animals or subject human life to the needless danger of
in vivo testing.
The great computational power of today's highly sophisticated
computer systems and the very abundant quantity of detailed medical
research information that is available for each of the major body
components, makes possible the modeling of the dynamics of the
Glucose-Insulin-Glucagon System.
Today's digital computer systems permit the many time and func-
tion dependent quantities of a biological system of this magnitude
to be calculated continuously on an almost instantaneous basis over
the time interval of interest and then to be plotted graphically for
visual use.
This thesis is an attempt to model the Glucose-Insulin-Glucagon
System of a 17.5 kilogram dog using the medical research data that
has been found, and the Continuous systems Modeling Program (CSMP)
of the 360 Digital Computer. Once the system has been modeled, it
will be exercised with glucose and insulin loads and the results com-
pared with the in vivo canine test data obtained by Stanley M.
Finkelstein, et al, (27) and R. C. de Bodo, et al (16).
The approach taken to develop the model for the dynamics of the
lucose-Insulin-Glucagon System was to determine the major body com-
ponents (liver, pancreas, and body muscle) involved in controlling
xi
the blood glucose dynamics and how these body components are affected
by the concentrations of various hormones (insulin, glucagon, adrena-
line, and glucocorticoids) and gluconeogenic substrates (amino acid,
lactate, and glycerol) in maintaining the blood glucose concentration
at approximately 100 mg/100 ml.
Since glucose is transported through the body by the blood, it
was necessary to determine how the blood is distributed throughout the
body and at what rates the blood is supplied to the major glucose
body components as well as other parts of the body. It was also nec-
essary to determine the pathway by which glucose travelled (blood
plasma-interstitial fluid-intravellular fluid) when leaving the blood
to be either converted to glycogen, lactate, or fat inside the cell
or temporarily stored as glucose in the blood plasma or interstitial
fluid. The volumes of blood plasma, interstitial fluid, and intra-
cellular fluid together with estimates of the transport constants
(admittances) of the capillary walls and cell membranes were used
to establish system time constants which are the primary factors in
the short term dynamics of the Glucose-Insulin-Glucagon System.
Once the major body components of the Glucose-Insulin-Glucagon
System have been modeled, the Continuous System Modeling Program
(CSMP) for the IBM System/360 was used to simulate the entire
Glucose-Insulin-Glucagon System. CSMP provides a convenient format
for the simulation of a differential analog system on the IBM 360
System.
To facilitate converting the Glucose-Insulin-Glucagon System
into the CSMP format, a set of mnuemonics was developed to repre-
sent the many input and output variables for all of the functions
involved in the dynamics of the Glucose-Insulin-Glucagon System.
After the CSMP model of the Glucose-Insulin-Glucagon System was
developed, it was exercised by providing both glucose and insulin






The basal blood glucose concentration level of approximately
100 mg/100 ml for a canine is maintained at this level by a number
of biological mechanisms which are capable of either supplying
glucose to or taking glucose from the blood. The blood glucose con-
centration will rarely go above 150 mg/100 ml in healthy systems
even after a heavy carbohydrate or protein meal, and will seldom fall
below 60 mg/100 ml, even after strenuous physical exercise.
Glucose Sources/
Glucose is capable of being supplied to the blood by three major
sources:
1. Food ingestion; carbohydrates and protein
2. Gluconeogenesis
3. Glycogenolysis
Both food ingestion and glycogenolysis are capable of increasing
the blood glucose concentration level in a matter of minutes (18),
but are not capable of sustaining the increased glucose concentration.
Gluconeogenesis is the primary source of glucose when no food is
being digested, but is not capable of a quick response to blood
glucose requirements, usually requiring fifteen to thirty minutes
for glucose derived from lactate (24) and one to two hours for the
glucose derived from amino acids (62) (see Figures 1, 2, and 3).
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FIGURE 1 	 ENDOCRINE CONTROL OF GLUCOSE METABOLISM*
FIGURE 1 illustrates metabolism of glucose during periods of dietary intake of
excess carbohydrate. The secretion of insulin promotes the snythesis of hepa-
tic and muscle glycogen, the synthesis of fats and depresses hepatic gluconeo-
genesis. 	 FIGURE 2 depicts the change in the situation at the oast of hypo-
glycaemia. 	 Insulin production declines and muscle and fat tissues are thus
deprived of glucose. There is an outpouring of adrenaline from the adrenal
medulla which acts at various sits to raise the blood sugar. (a) hepatic
phosphorylase is activated; (b) there is a release of lactate from muscle and
glycerol from fat tissues which act as raw material for hepatic gluconeogenesis;
(c) activates, via the hypothalamus, the secretion of A.C.T.H. by the anterior
pituitary gland. There is also secretion of glucagon from the pancreas which
reinforces the action of adrenaline on hepatic phosphorylase. 	 FIGURE 3 
shows later stages in the response to hypoglycaemia. A.C.T.H. from the anter-
ior pituitary gland activates the adrenal cortex which secretes glucocorticold
hormones. These hormones act in various ways to maintain supplies of glucose
for the C.N.S.; (a) they antagonize the uptake of glucose by muscle and fat
cells; (b) cause a release of amino acids from muscle which act as raw material
for hepatic gluconeogenesis; (c) increase the amounts of those hepatic
enzymes concerned in gluconeogenesis.
*From Clegg & Clegg (13).
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FIGURE 2 	 ENDOCRINE CONTROL OF GLUCOSE METABOLISM*
FIGURE 3 	 ENDOCRINE CONTROL OF GLUCOSE METABOLISM*
*From Clegg & Clegg (13).
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Food ingestion. Ingested food carbohydrates are converted
directly to glucose by the digestion process and are absorbed by the
blood in the alimentary tract. The resulting increased blood glucose
concentration is then available for conversion into glycogen in
either the liver or body muscle, fat in adipose tissue, or lactate by
the red blood cells. All of these conversions are influenced in vary-
ing degrees by the insulin concentration level of the blood.
Food protein is digested and converted into amino acids by the
alimentary tract. Amino acids, which are one of the major gluco-
neogenic substrates, are transported by the blood from the alimen-
tary tract to the liver where they are converted to glucose by
gluconeogenesis.
Gluconeogenesis. Gluconeogenesis is the biological mechanism
by which the liver is capable of converting the gluconeogenic sub-
strates of lactate, amino acids, and glycerol into glucose. The
rate at which glucose is produced from gluconeogenesis is determined
by the concentration levels of the hormones: insulin, glucagon,
adrenaline, and glucocorticoids. By affecting both the liver and
the origin of the gluconeogenic substrates, insulin is capable of
inhibiting gluconeogenesis while glucagon, adrenaline, and gluco-
corticoids all increase the rate of gluconeogenesis.
Glycogenolysis. Glycogenolysis is the biological mechanism
whereby the glucose that has been stored as glycogen in the liver and
body muscle is converted back to glucose. In the liver, the glycogen
5
is converted back to glucose under the influence of glucagon while
the glycogen stored in the body muscle is first converted to lactate
under the influence of adrenaline and then returned to the blood and
converted to glucose in the liver by gluconeogenesis.
The glycogen stored in the liver is capable of being very
rapidly converted to glucose by the action of the hormone glucagon,
approximately 10 gm/hr for a 17.5 kg canine (22, 63). Glycogen-
olysis in body muscle, release of lactate due to the hormone
adrenaline, is a relatively more time-consuming and slower process
in the production of glucose due to both the nature of muscle glyco-
genolysis and the subsequent gluconeogensis in the liver required to
convert lactate to glucose (23).
Use of Glucose 
The primary uptake of glucose from the blood is by the central
nervous system (CNS) with most of the glucose being supplied to the
brain. Glucose is supplied to the CNS at an almost constant rate
except under the conditions of prolonged fast when body protein is
conserved and energy sources other than glucose are made available
to the CNS. Glucose is also removed from the blood resulting in
synthesis of glycogen in both the liver and body muscle. In body
muscle, insulin is involved in an active transport mechanism, (see
Figure 4), that carries glucose across the cell membrane from the
interstitial fluid into the intracellular fluid of the cell where

















Liver. The liver is the primary body component for maintaining
the blood glucose level at approximately 100 mg/100 ml. The liver of
a 17.5 kg canine weighs approximately 550 gm (1). It is capable of
converting glucose to glycogen at a. maximum rate of about 8 gm/hr (18)
and can store 19 grams of glycogen (16) which can be converted back
to glucose at a near maximum rate of 10 gm/hr (22, 63) when needed to
quickly increase the blood glucose concentration.
The supply of blood carrying glucose, gluconeogenic substrates,
and hormones to the liver is by way of the portal vein and the
* From Clegg & Clegg (13).
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hepatic artery (see Figure 5). The portal vein brings blood to the
liver at a rate of approximately 532 ml/min from the stomach, intes-
tines, pancreas, and spleen, while the hepatic artery's blood supply
of approximately 276 ml/min is directly from the cardiac output by
way of the descending aorta.
Under steady state (short term fasting period of twelve to
twenty-four hours) the liver produces glucose by means of gluco-
neogenesis at a rate of 1.4 gm/hr (see Figure 6). Of this 1.4 gm/hr,
0.4 gm/hr is derived from the gluconeogenic substrate lactate which
was produced by the red blood cells from blood glucose in what is
known as the "Cori" cycle. The remaining 1.0 gm/hr of liver glucose
is derived from the gluconeogenic substrates of amino acids and
glycerol at rates of 0.8 gm/hr and 0.2 gm/hr, respectively (8). The
kidney glucose contribution is 0.4 gm/hr (20).
The rates of glucose production from both gluconeogenesis and
glycogenolysis, and the rate at which glucose is converted to glyco-
gen are controlled by many factors; the primary factors being the
blood concentration levels of the gluconeogenic substrates and the
hormones insulin and glucagon. Over a short period of time, less
than thirty minutes, insulin and glucagon dominate in the control of
the blood glucose concentration level, while over longer periods of
time, particularly during fasting, these three factors plus the blood
concentration levels of adrenaline and glucocorticoid control the
rate of glucose production in the liver and; consequently, also the












































































































































Pancreas. The function of the pancreas in the regulation of the
blood glucose concentration level is to supply the hormones insulin
and glucagon to the blood in response to the blood glucose concentra-
tion level. High gl ucose concentration levels will cause increased
amounts of insulin and decreased amounts of glucagon to flow from the
pancreas into the blood of the portal vein. Low blood glucose con-
centration levels will have the opposite effect. Insulin output from
the pancreas will be decreased and the glucagon output increased.
The pancreas of a ¹7.5 kg canine weighs approximately 58 grams,
has a blood flow through it of approximately 46 ml/min (34) and has
basal insulin and glucagon outputs of approximately ¹70 ng/min and
¹5 ng/min, respectively, for basal blood concentration levels of
0.5 ng/ml¹ for insulin and 0.06 ng/ml for glucagon. The pancreatic
outputs of both insulin and glucagon to a step input of glucose is
biphasic, meaning that the initial output response is an overshoot
followed by a lower steady state output level that is a more linear
function of the glucose concentration level.
High blood insulin concentration levels affect the blood glu-
cose concentration level by reducing the rate of gluconeogenesis in
the liver, by increasing the rate at which glucose is taken up in
the body muscle to be converted to glycogen, and also by inhibiting
the output of the gluconeogenic substrate amino acids. High blood
concentration levels of glucagon increase the rates of both gluconeo-
¹See Derivation of Pancreas Model for details about flow rates
and basal blood concentration level for insulin and glucagon.
¹¹
genesis and glycogenolysis in the liver causing the blood concentra-
tion of glucose to also increase.
Body muscle. Body muscle accounts for approximately forty per
cent of the total weight of a canine. 2 The three main functions of
body muscle in the dynamics of the Glucose-Insulin-Glucagon System
are:
¹. Convert glucose, which has entered the muscle cells
under the influence of insulin, into glycogen during
periods of high glucose concentration levels in the
blood. The body muscle is capable of storing
approximately ³8 grams ³ of glycogen.
2. To convert the stored glycogen back to lactate under
the influence of adrenaline during periods of low
blood concentration levels of glucose, the lactate to
be converted to glucose in the liver by gluconeogenesis.
Adrenaline is secreted by the adrenal medulla when the
CNS senses a low concentration level of glucose in the
blood.
3. To convert muscle protein to amino acids under the
influence of glucocorticoids, again during the periods
2
The forty per cent figure for the body muscle of a ¹7.5 kg dog
is based on body muscle comprising forty per cent of the skeleton
weight of a 70 kg man. Posefsy, et al, Amino Acid Balance Across 
Tissue of the Forearm in Postabsorptive Man, Journal of Clinical
Investigation, Volume 48, ¹969, page 2279
³Thirty-eight grams of body muscle glycogen storage is extra-
polated from the ¹50 grams of body muscle glycogen storage capability
for a 70 kg man. Cahill, Starvation in Man, The New England Journal
of Medicine, March, ¹969, page 669.
of low blood concentration levels of glucose, with
the amino acids being converted to glucose in the
liver by gluconeogenesis. This is a slow process
requiring several hours (62) primarily due to the ac-
tion of glucocorticoids on muscle protein and the
sequence of events that must take place prior to this
action (sensing of low blood glucose concentration and
release of CRF by the hypothalamus--the secretion of
ACTH from the anterior pituitary due to CRF--and then
the release of glucocorticoids from the adrenal
cortex in response to ACTH). Adrenaline also acts
along this same pathway to reinforce the secretion

















*From Clegg & Clegg (1³).
Substrates 
Amino acids. The gluconeogenic substrates--amino acids, lactate,
and glycerol--supply the major portion of the raw materials used by
the liver to produce glucose. Of the twenty odd amino acids found
in the blood, only alanine is significant in gluconeogenesis and the
regulation of the blood glucose concentration. Amino acids enter the
blood directly from the digestion of protein in the alimentary tract
and also from the breakdown of muscle protein. The muscle protein
source of amino acid is regulated by both insulin and glucocorticoids.
Insulin works to decrease the supply of amino acids from body muscle
while glucocorticoids increase the amino acid supply. The effects of
insulin requires only thirty to sixty minutes (56) while glucocorti-
coids require one to two hours (62) and appears to be the primary
control of blood glucose concentration levels during short term fast-
ing (less than twenty-four hours).
Lactate. The gluconeogenic substrate lactate also has two
sources, the first source being the breakdown of glycogen stored in
body muscle under the influence of adrenaline. This is a relatively
fast process requiring less than fifteen minutes (26). The second
source of lactate is the red blood cells. The red blood cells
extract glucose from the blood plasma, convert this glucose to
lactate, and then return the lactate to the blood plasma to be con-
verted back to glucose by the liver. This cycle is known as the "Cori"
cycle and accounts for approximately twenty per cent of the total
steady state output of glucose produced by gluconeogenesis.
¹4
Glycerol. The glycerol contribution to the steady state glu-
cose output from the liver is approximately ten per cent. The major
source of glycerol is adipose tissue (fat) and is affected by the
blood concentration, level of adrenaline. The major contribution of
glycerol to the production of glucose is during the long term fasting
when the normal basal blood concentration level of glycerol is
increased by almost a factor of three and becomes one of the major
gluconeogenic substrates.
Body Fluids 
Blood. Glucose, the gluconeogenic substrates, and the hormones
that control all the body functions that regulate the blood glucose
concentration level are transported throughout the body by the blood
and the circulatory system. The blood volume for a ¹7.5 kg canine
is approximately ¹600 ml with the cardiac output being 2200 ml/min.
The blood flow to the liver of approximately 800 ml/min is by way of
the alimentary tract and the hepatic artery. The alimentary tract
provides approximately twenty-five per cent of the cardiac output to
the liver, and the hepatic artery twelve per cent. Blood flows out
from the liver through the hepatic vein and is returned to the heart
by way of the inferior vena cava. The other major body components
involved in glucose dynamics are supplied blood from the descending
aorta, and the subclavian and carotid arteries. Blood is returned
to the heart through the superior and inferior vena cava. The blood
circulatory path through the body is shown in Figure 5.
The blood flow rates and the approximate distributed blood vol-
umes for the major body components are shown in Table I.
Interstitial and intracellular fluids. The site of the chemical
reactions involved in both the metabolizing and synthesizing of glu-
cose is inside the cell, but before the glucose, gluconeogenic sub-
strates, and hormones involved in the Glucose-Insulin-Glucagon
dynamics can reach the interior of the cell, they must pass through
the capillary walls that separate the blood circulatory system from
the body's interstitial fluid, and then pass through the outer mem-
brane of the cell that separates the interstitial fluid from the
intracellular fluid of the cell (see Figure 8). The ratio of blood
to interstitial fluid to intracellular fluid is approximately
¹:2.4:7, respectively, (¹³, 28) (see Figure 9). These body fluid
compartments, or reservoirs, are significant in the short term
(thirty minutes to two hours) dynamics of the
Glucose-Insulin-Glucagon System.
Transport. The transport of glucose, gluconeogenic substrates,
and hormones across the capillary walls and cell membranes are for
the most part at fixed rates, varying only as a function of body
component and substance being transported, with the exception of the
transport of glucose across the cell membranes of the body muscle.
Insulin which is secreted into the blood by the pancreas during per-
iods of high blood glucose concentration levels causes glucose to be
transported across the cell membranes from the interstitial fluid
into the intracellular fluid of the cell at an increased rate by what























	 	 	 	
	PLASMA	 TISSUE 	 CELL 	 CELL







Active transport is the process by which a substance is trans-
ported across a membrane by another substance. This process involves
energy and is capable of transporting substances against high concen-
tration gradients. The potassium-sodium concentration gradient bet-
ween the red blood cells and blood plasma is an example of active
transport in action. The red blood cell contains twenty times more
potassium than the blood plasma, while the blood plasma contains
twenty times more sodium than the red blood cell.
¹9
SECTION III
DEVELOPMENT OF OVERALL BODY MODEL 
The Glucose-Insulin-Glucagon dynamics for a ¹7.5 kg canine
involves the transport of glucose, substrates, and hormones to all
parts of the body by way of the circulatory system. The circula-
tion through the major body components is shown in Figure ¹0. The
physiological parameters for the blood flow, blood volume, inter-
stitial fluid, intracellular fluid, organ dry weight, and admittance
for the major body components and the circulatory system are listed
in Table I. These parameters have been derived, for the most part,
from data in the following references (¹, 8, ¹4, 20, ³0, ³4, 57) and
by extrapolation of these data with the following assumptions and
facts:
1. Body fluid (blood, interstitial and intracellular)
accounts for approximately seventy-one per cent of
total body weight.
2. The ratio of blood, interstitial fluid, and intra-
cellular fluid is approximately ¹.0 : 2.4 : 7.0.
3. Body muscle accounts for approximately forty per
cent of the total body weight.
4. Tissue dry weight accounts for approximately nine
per cent of the total body weight.
5. Skeleton accounts for approximately twenty per cent
of the total body weight.





6. The disappearance rate for both insulin and
glucagon is approximately ten per cent per minute.
7. Blood hematocrit (ratio of red blood cell volume
to the total blood volume) is approximately twenty-
eight per cent.
The last entry in Table I "Other" has been included to account
for the difference between the entry "Total" and the sum of the body
component entries.
Figure ¹0 shows the major body components that have been used
to model the Glucose-Insulin-Glucagon System. In this figure, Body
Muscle is meant to also include the front paws and hind legs of the
canine, while the body component labeled "Kidney-Other" combined
both the "Kidney" and "Other" entries of Table I. The right side of
the heart, the lungs, and the left side of the heart have been drawn
serially to better visualize the flow of blood through these organs.
Although the interconnecting arteries and veins between the
major body components are shown as having volume in the Glucose-
Insulin-Glucagon Model Block Diagram (Figure ¹0), the total body
blood volume of ¹6¹9 ml has been apportioned to the major body com-
ponents on the basis of organ weight. Adjustment of the blood volume
apportionment has been made where data indicated that the body com-
ponent had either a higher or lower than average blood to weight ratio.
Such is the case for the heart. The V¹ compartment for each of the
major body components represents the plasma part of the blood that has
2¹
been apportioned to each of the major body components.
Each of the major body components in the
Glucose-Insulin-Glucagon Model Block Diagram of Figure ¹0 has been divided into
three sections, V¹, V2, and V³ to represent the volumes of the plasma,
interstitial fluid, and the intracellular fluid, respectively. The
values of these volumes are listed in Table I. The line separating
V¹ from V2 represents the membrane (capillary wall) that separates
the plasma from the interstitial fluid. This membrane has a trans-
port constant (admittance) K¹2 associated with it for each of the
substances, glucose, hormones, and substrates, that permeates
through this membrane. 	 Likewise, the line separating V2 from V³
represents the cell membrane separating the interstitial fluid from
the intracellular fluid of the cell. Associated with this membrane
is a transport constant (admittance) K2³ for each of the substances
that permeates this membrane.
The overall body admittance for glucagon (K¹2 in series with
K2³) has been determined from the data of J. L. Chiasson, M.D. and
Associates (¹¹), and J. P. Palmer, M.D. and Associates (5³). 	 From
the data of Chiasson, glucagon input rates of 50, 25, and ¹5 ng/kg/min
resulted in glucagon concentration levels of 5.06, 2.45, and ¹.7
ng/ml, respectively. The glucagon admittance was calculated from:
Y = AR/AC 	 (1)
where:
Y = overall body glucagon admittance (ng/min)/(ng/ml)
AR = glucagon input rate for ¹7.5 kg canine (ng/min)
AC = glucagon concentration (ng/ml).
For three sets of data from Chiasson:
Y - (50 x ¹7.5)/5.066 = ¹72
Y = (25 x ¹7.5)/2.45 = 178
Y = (¹5 x ¹7.5)/¹.7 	 = ¹54
Average admittance: Y = ¹68 (ng/min)/(ng/ml).








appearance time constants ( r) are approximately ten minutes, the
electrical analog for glucagon disappearance transient becomes:
-(Y/V)t
AW = (AC 1 ) (V) (e
1- = V/Y
where:
AC1 = initial glucagon concentration (ng/ml)
AW = total weight of glucagon in volume (V) (ng)
V = total volume of plasma and interstitial fluid in 17.5 kg
canine (ml)
Y = overall body glucagon admittance (ng/min)/(ng/ml)
π = glucagon disappearance time constant (min).
Since:
= V/Y
for 	 V = 4017 ml, 7= 10 min
Y = 4017/10 = 402 (ng/min)/(ng/ml).
There is a greater than two to one difference between the overall
body glucagon admittances calculated from the data of Chiasson and
Palmer, 168 and 402 (ng/min)/(ng/ml), respectively. The probable
reason for the two to one difference between the two calculated values
for the overall body glucagon admittances are:
1. The data of Chiasson was obtained by administering
glucagon, over a substantial period of time at
rates which produced glucagon concentrations that
were very high compared to physiological levels,
thus, reaching a steady state condition and also
minimizing the binding effect that glucagon has
with tissue.
2. For the data of Palmer, glucagon was secreted from
the pancreas over a relatively short period of time
in response to a pulse of arginine, thus, the bind-
ing effect between glucagon and tissue is signif-
icant since it lowers the glucagon concentration by
removing glucagon from the blood plasma and
interstitial fluid. This causes the overall body
glucagon admittance (calculated from transient data)
to be higher than when calculated from the steady
state data of Chaisson.
Since the conditions under which the Glucose-Insulin-Glucagon
Model will be tested fall somewhere between the high level steady
state conditions of Chiasson's data and low level transient con-
ditions of Palmer's data, the average of the two overall body
glucagon admittances will be used.
Averaging the glucagon admittances determined from the data of
Chiasson and Palmer, the overall body glucagon admittance becomes:
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Y = (168 + 402)/2 = 285 (ng/min)/(ng/ml)
The overall body glucagon admittance is the parallel combina-
tion of all the series glucagon admittance (AK12)¹ between the plasma
and the interstitial fluid, and the glucagon admittance. (AK2³) between
the interstitial fluid and the intracellular fluid of the cell. Since
data was not found which would permit the determination of (AKl2 and
AK2³), and many references (6, l³) have been made to the fact that
equilibrium is reached very quickly between the plasma and inter-
stitual fluid concentrations, it has been assumed that the (AKl2)
admittance was twice as great as the (AK2³) admittance. For an





From the data of Palmer, the insulin disappearance curves are
very similar to the disappearance curves for glucagon; also from the
data of Norfleet (51), the basal secretion of insulin was approx-
imately ten times that of glucagon, indicating that the insulin and
glucagon overall body admittances are equal since the basal concen-
tration of insulin is approximately ten times that of glucagon,
0.5 ng/ml, 0.06 ng/ml, respectively. For these reasons, and for the
lack of additional insulin data, the admittances that were determined
for glucagon have been used for the insulin admittances.
1
Explanation of mneumonics appears in Section VII.
Since the major disappearance of glucose from the system is
either by way of the brain or body muscle, the glucose admittances
(GK2³C, GK2³M) between the interstitial and intracellular fluids of
these organs are the only interstitial to intracellular fluid admit-
tances used. The admittances for the brain have been determined on
the basis of 2³.0 mg/min of glucose being absorbed in the intracell-
ular fluid (V³C) of the brain at a glucose concentration (GC³C) of
0.0 mg/ml (4, 8, ³l) and a glucose concentration (GC2C) of approx-
imately 0.6 mg/ml in the interstitial fluid of the brain. The
resulting admittances (GK12C) and (GK2³C) have been calculated to be
76.6 and ³8.³ (mg/min)/(mg/ml), respectively. The (GK2³M) admit-
tance for muscle involves active transport (a function of insulin)
and is described in the section on Development of Muscle Model
(Section VI). The glucose admittances between the plasma and the
interstitial fluid for the other body components was made equal to
the corresponding glucagon admittance simply for the lack of data to




DEVELOPMENT OF LIVER MODEL 
The liver is the primary body component in controlling the blood
glucose concentration. The liver of a 17.5 kg canine weighs approxi-
mately 550 gm, has a blood flow through it of approximately 800 ml/min,
and is capable of storing approximately 19 gm of glycogen.
During periods of low blood glucose concentration, the liver
supplies glucose to the blood by the processes of glycogenolysis
(glycogen to glucose) and gluconeogenesis (substrates to glucose).
Both of these processes are mediated by the blood concentrations of
gluconeogenic substrates and hormones. During basal periods (steady
state, short term fasting) gluconeogenesis in the liver is the primary
process involved in supplying glucose to the blood and controlling
the blood glucose concentration. During periods of high blood
glucose concentration, the glucose outputs from both glycogenolysis
and gluconeogenesis are reduced and the primary function of the liver
is to convert blood glucose to glycogen to be stored in the liver for
later use in the process of glycogenolysis.
The liver model for the 17.5 kg canine involves developing math-
ematical models (transfer function) for the following liver function:
1. Conversion of glucose to glycogen
2. Conversion of glycogen to glucose (glycogenolysis)
3. Conversion of amino acids to glucose (gluconeogenesis)
4. Conversion of lactate to glucose (gluconeogenesis)
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5. Conversion of glycerol to glucose (gluconeogenesis)
These mathematical models describe the rates of liver glucose
output and input in terms of the blood concentrations of glucose, glu-
coneogenic substrates, the hormones insulin and glucagon, and the
quantity of glycogen stored in the liver.
The approach taken to develop the mathematical models was to
determine which of the above factors were primarily responsible for
the control of the rate of liver glucose output and input, and then
to describe the basal, maximum, and minimum liver glucose output and
input rates as a continuous function of these factors. These contin-
uous functions have been derived directly from applicable data, from
extrapolation of comparable data, or intuitively from general physical
phenomena. The dependent-independent relationship of the liver
mathematical models are in terms of first order effects only, since
this is the form of most of the data and to describe a mathematical
model of the liver otherwise, would be extremely time-consuming and
awkward, if not impossible. Following is a detailed explanation for
the derivation of the mathematical models of each of the above-
mentioned five liver functions.
Conversion of Glucose to Glycogen 
The data used to develop the mathematical model for the conversion
of glucose to glycogen is principally contained in references (³, 6,
18, 49). From this data, it has been determined that the rate at
which glucose is converted to glycogen in the liver is a function of
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the blood glucose, insulin, and glucocorticoids concentrations per-
fusing the liver and also the quantity of glycogen that is stored in
the liver.
SEW3L = (Kl) fl (GClL) f2 (IClL) f3 (EW3L)
where
SEW3L - is the rate at which glucose is converted to glycogen,
(mg/min)
Kl 	 - the maximum rate at which glucose can be converted to
glycogen, (mg/min)
GC1L - the glucose concentration in the blood plasma of the
liver, (mg/ml)
IClL - the insulin concentration in the blood plasma of the
liver, (ng/ml)
EW3L - the quantity of glycogen that is stored in the
intracellular fluid of the liver, (gm).
The glucocorticoid function has not been included because of a
lack of data, the overall complexity of the function, and the time
delay (approximately two hours) before glucocorticoids are effective.
The mathematical model that has been derived is:
-IClL/2.0
SEW3L = (137.5)(GClL/4)(1 -e 	 (4)
/1 - EW3L/550
x 1 	 -IClL/l.56
(0.029)(l.5 - 0.5e 	 ) ( GCIL )
The Kl term has been derived from the data of (6) and (18). The
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data of (6) indicates a half maximum rate of 0.5%/hr of liver weight
for the conversion of glucose to glycogen at a glucose concentration
of 2.0 mg/ml. The data of (18) reports a 1.1%/hr of liver weight
conversion at a glucose concentration of 2.5 mg/ml. 	 If it is assumed
that the conversion of glucose to glycogen varies linearly as a func-
tion of glucose concentration and that this function saturates at a
glucose concentration of 4.0 mg/ml, then averaging the maximum rates
of (6) and (18) yields a rate of approximately 1.5%/hr of liver
weight at a glucose concentration of 4.0 mg/ml. For the 550 gm liver
of a 17.5 kg canine, this equates to a maximum conversion rate of
glucose to glycogen of 8.25 gm/hr or 137.5 mg/min.
The insulin function
- IC1L/2.0
(1.0 - e 	 (5)
has been determined from the data of (3). This data gives a near
maximum conversion of glucose to glycogen of 495 umoles/hr/30 gm of
liver, at a glucose concentration of 1.0 mg/ml and an insulin infu-
sion rate of 0.04 - 0.2 units/kg/hr. This level of insulin infusion
results in a near maximum physiological insulin concentration in the
blood. The rate of 495 umoles/hr/30 gm of liver converts to
1.63 gm/hr for the 550 gm liver of a 17.5 kg canine. Also the data
of (3) for the pancreatectomized dog indicates there is no conversion
of glucose to glycogen when insulin is not present. The insulin func-
tion produces (SEW3L) equal to (0.0, 34.3 mg/min) for no and maximum
insulin, respectively, and basal glucose. The insulin function (5)
produces a 3 : 1 increase in the conversion of glucose to glycogen
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when the maximum insulin effect is compared to that of the basal insu-
lin concentration (IC1L) of 0.78 ng/ml.
The glycogen storage function
(6)
has been derived from the data of Mortimore (49) (see Figure 12) and
has been incorporated into the mathematical model to account for the
dependence of the liver's glycogen storage capacity upon the liver's
blood plasma concentrations of both glucose and insulin. This function
is designed to allow glucose to be converted to glycogen whenever
the maximum storage capability of the liver has not been attained for








blood plasma. Although this function controls the rate of glucose
to glycogen conversion almost in proportion to the difference between
the amount of glycogen the liver is capable of storing and the actual
amount of glycogen that is stored in the liver, this function has not
been designed to simulate actual rate data simply because this data
is not available in a form convenient to model, (See Conversion of
Glycogen to Glucose for a partial justification for this derivation.)
The ability of the liver to store glycogen as a function of
insulin concentration is based on a 2200 gm human liver being able
to store 75 gm (3.5% of liver weight) of glycogen, (8) and (49).
From the data of (49) (see Figure 12), it was possible to determine
the glycogen content of the liver with no insulin (28 mg/gm) and
the glycogen content of the liver (42 mg/gm) with the maximum
effective physiological concentration of insulin, both glycogen
storages being at a glucose concentration of approximately 2.4 mg/ml.
The increase in glycogen storage capability is approximately fifty
per cent from no insulin to the maximum effective physiological con-
centration of insulin. Assuming the insulin storage function to be
approximately exponential and the minimum, basal, and maximum
storage capability to be 2.9, 3.5, 4.4% of liver weight, respectively,
the insulin storage function becomes
- IC1L/1.56
(0.029) (1.5 - 0.5e 	 ). 	 (7)
The glucose concentration storage function is also derived from
the data of (49) (see Figure 12). For both no insulin and maximum
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effective insulin a sixty per cent increase in the glucose concentra-
tion (GC1L) resulted in approximately a twenty-two per cent increase
in the maximum glycogen storage capability of the liver, so that the
glucose concentration storage function becomes
(8)
and the combined insulin-glucose concentration storage function, becomes
(9)
The actual glycogen storage fraction is
EW3L/550 	 (10.)
By subtracting the ratio of the actual glycogen storage fraction
to insulin-glucose concentration storage function from 1.0, a measure
of the difference between the glycogen storage capability of the
liver and the actual glycogen stored in the liver is obtained.
(11)
This function is very nearly proportional to the difference bet-
ween the glycogen storage capability and the actual glycogen stored.
The computer program describes (SEW3L) in terms of two additional
variables (GLYSTO and GLUGLY). These two variables have been intro-
duced as part of a limit function so that the storage function, and
likewise (SEW3L), never becomes negative.
34
Conversion of Glycogen to Glucose
Glycogen is capable of being converted back to glucose at a max-
imum rate of approximately 10 gm/hr (167 mg/min), (22, 63) by the
process of glycogenolysis. From the data of (22, 49, 63), the conver-
sion rate of glycogen to glucose is a function of the quantity of
glycogen stored in the liver and the blood concentrations of insulin,
glucagon, and glucose perfusing the liver.
GR22LI = (K2) f1 (EW3L) f2 (ACIL) f3 (GCIL, IC1L)
where:
GR22LI 	 - the rate at which glycogen is converted to glucose
in the liver (mg/min)
K2 	 - the maximum rate at which glycogen is converted to
glucose (mg/min)
ACIL 	 - the glucagon concentration in the blood plasma of
the liver (ng/ml)
ICIL, EW3L- the same as defined under (Conversion of Glucose
to Glycogen.)
Glucocorticoids also affect the rate at which glycogen is con-
verted to glucose, but this function has not been included for the
same reasons previously given.
The mathematical model that has been developed for the conver-
sion of glycogen to glucose is:
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(12)
The maximum conversion rate of 167 mg/min from glycogen to glucose
has been verified from the data of (22). This data gives the hourly
maximum rates of glucose production (gluconeogenesis) from the
livers of fasted rats as a function of the glucagon concentration
of the perfusing blood plasma, and also similar data but for the
livers of fed rats. By taking the difference between these two sets
of data, the glucose produced from glycogen (glycogenolysis) is
obtained. The maximum rate of glucose production from glycogen is
105 umoles/gm-liver/hr. For the glucose molar weight of 180 gm and
a 550 gm canine liver, this rate becomes 10.4 gm/hr (173 mg/min).
By plotting the above difference data, it is possible to deter-
mine the rate at which glucose is produced from glycogen as a func-
tion of glucagon. Although the glucagon concentrations required to
produce glucose are higher by nearly a factor of three than the aver-
age physiological glucagon concentrations, by considering the fact
that the liver rapidly degrades glucagon (2, 64) it is possible to
justify using this data to model the glucagon function. Assuming
that the basal glucagon concentration (0.09 ng/ml) in the liver blood
plasma is capable of producing glucose at one-third its maximum rate,
then the mathematical model for the glucagon function becomes:
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(13)
The mathematical model for the glycogen storage factor:
(14)
has been derived from the data of (63). When glucagon was added to
the liver perfusion system to produce near maximum glycogenolysis from
a rat liver that had a glycogen storage of ten per cent of maximum,
glucose was produced at a rate that was thirty per cent of the maxi-
mum conversion rate of glycogen to glucose.
The insulin and glucose term
(15)
is the complement of the last term (11) derived for the mathematical
model for the conversion of glucose to glycogen. This term has been
included to cause glycogen to be converted to glucose to maintain
the dynamic equilibrium that exists between glycogen storage (EW3L),
insulin concentration (ICIL), and glucose concentration (MO, as
reflected in the data of (49), (see Figure 12). The basis for the
derivation of this term is the fact that glycogen is converted to
glucose at a rate that is approximately proportional to the differ-
ence between the starting glucose concentration level and the equilib-
rium glucose concentration level when both the initial glycogen stor-
age (EW3L) and insulin concentration (ICIL) levels are equal. For
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the control data, the initial rate at which glycogen is converted to
glucose for low and high glucose concentration levels is 98 and 42
mg/hr/liver, respectively. The difference between the starting glu-
cose concentration level and the equilibrium glucose concentration
level for low and high glucose concentration levels is 200 and 110
mg/100 ml, respectively. On this basis, the mathematical model for
this term is derived form the ratio of the difference between the
equilibrium and actual glucose concentration levels and the equili-
brium glucose concentration level.
Equil. Gluc. Conc. -- Act. Glu. Conc. 
Equil. Gluc. Conc.
The equilibrium glucose concentration term is:
The term is a composite of a glycogen storage term:
and an insulin term:
The glycogen term (17) has been derived from the low and high glu-
cose concentration control data points at 150 minutes, (see Figure 12).





for 550 gm canine liver) resulting in glucose concentration levels of
230 and 380 mg/100 ml.
For the insulin data at 150 minutes, a factor of three is
required to adjust the glycogen term resulting in the insulin
term (18).
When the equilibrium glucose concentration term is substituted
into the ratio term, the resulting insulin and glucose term becomes:
(19)
The computer program contains two additional terms (Factor and GLGL)
which have been included to limit GR22L1 to only positive values.
Conversion of Amino Acids to Glucose
The conversion of amino acids to glucose in the liver is prim-
arily a function of the liver blood plasma concentration of amino
acids, (43). The blood plasma concentrations of amino acids are a
function of the concentrations of both insulin and glucagon, (10, 56).
From the data of (43), a mathematical model has been developed
describing the rate at which glucose is produced from amino acids
as a function of the normalized basal amino acid concentration.
(20)
Where GR22L2, the rate at which glucose is produced from amino acids,
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is made to equal the basal glucose production rate of 13.1 mg/min
at a normalized basal amino acid concentration (AAN) of I.0, and
122 mg/min , for a normalized amino acid concentration of 3.0.
The regulation of the normalized basal liver blood plasma amino
acid concentration is by way of the body muscle blood plasma concen-
trations of insulin (ICIM) and glucagon (ACIM). The data of Chiasson
(10), shows a near twofold increase in the rate at which the amino acid
alanine is converted to glucose when glucagon is administered at near
maximum physiological levels. Although Chiasson could not preclude that
this doubling rate was not due to an increase in the liver blood plasma
amino acid concentration, the data of (43) and the result of other
workers has shown that with fixed amino acid concentration levels,
glucagon has increased gluconeogenesis minimally. It is thus con-
cluded that glucagon regulates the liver blood plasma amino acid
concentrations. The mathematical model for the normalized amino acid
glucagon function becomes:
(21)
The data of (56) demonstrates that high physiological levels of
insulin are capable of reducing the amino acid concentration in the
venous forearm blood plasma by a factor of two. The mathematical




Combining both the glucagon and the insulin functions, (21, 22) the
mathematical model for the normalized amino acid concentration becomes:
(23)
Conversion of Lactate to Glucose 
Lactate is converted to glucose in the liver of a 17.5 kg canine,
under basal conditions, at a rate of 0.4 gm/hr (6.67 mg/min), extra-
polated from the data of (8). The maximum conversion rate appears
to be approximately ten times this rate under the conditions of high
lactate concentrations (22). In vivo high lactate concentrations
would be produced when glycogen stored in body muscle is converted
by glycogenolysis to lactate under the influence of adrenaline.
Because glucose produced from lactate is only a small part of the
total glucose production, the lactate-adrenaline function has not
been included. The more direct action of both glucagon and insulin
on the liver production of glucose from lactate (21, 22, 49, 54)
have been included in the mathematical model for the conversion of
lactate to glucose.
From the data of (21), glucagon has caused a three to one
increase in the production of glucose from lactate. Although this
data was with saturating lactate concentration, the data of (21)
corroborates a three to one variation capability in glucose produc-
tion from basal to saturating levels of lactate. The mathematical
model for the glucagon function becomes:
(24)
The data of (49, 54) indicate that there is approximately thirty
per cent reduction in the rate at which glucose is produced from
lactate from no insulin to a basal insulin concentration. The math-
ematical model for the insulin function becomes:
- ICIL/0.78
(1 + 0.5e 	 (25)






DEVELOPMENT OF PANCREAS MODEL 
The pancreas of a 17.5 kg canine weighs approximately 58 grams,
has a blood flow through it of approximately 46 ml/min, and secretes
both insulin and glucagon in response to the glucose concentration
of the blood plasma perfusing it. An increase in the blood plasma
glucose concentration will cause a corresponding increase in the
secretion of insulin and a decrease in the secretion of glucagon. A
mathematical model for the pancreas has been developed using the
data of (32, 40, 45), (see Figure 13).
The mathematical model for insulin is:
(27)
where:
IR 	 - is the rate at which insulin is secreted by the
canine pancreas (ng/min)
GCIP - is the blood plasma glucose concentration of the
pancreas (mg/ml).
This equation for the insulin output is a straight line approx-
imation of the data of (32), (see Figure 13). This equation when
limited by the CSMP computer program function LIR will cause no
insulin to be secreted from the pancreas for blood plasma glucose
concentrations below 0.73 mg/ml, and a maximum insulin secretion of




The insulin data of Figure 13 appears to be in error by a factor
of ten, since it is in conflict with latter data of (32). The data
of Figure 13 when extrapolated for a 17.5 kg canine on the basis of
body weight would produce a maximum insulin secretion rate of 14000
ng/min. The insulin secretion rate is much too high for the overall
body insulin admittance and would cause extremely high basal blood
plasma insulin concentrations. The later data of (32) correlates
with the data of (45) and would produce the basal blood plasma insulin
concentration of 0.5 ng/ml for the calculated overall body insulin
admittance. For this reason, the insulin data of Figure 13 has been
scaled down by a factor of ten.
*From Gerich (32).
44
The mathematical model for the pancreas glucagon function is:
(28)
where:
AR 	 - is the rate at which glucagon is secreted from the
canine pancreas (ng/min)
GCIP - is the blood plasma glucose concentration of the
pancreas (mg/ml).
This equation is also a straight line approximation of the data from
Figure 13. The maximum glucagon secretion is 60 ng/min when extra-
polated for a 17.5 kg canine. No glucagon is secreted for blood
plasma concentration above I.4 mg/ml. This low limit of zero is pro-
duced by the LAR limit function of the CSMP computer program. The
basal glucagon secretion is 16.8 ng/min and will cause a basal blood
plasma glucagon concentration of 0.06 ng/ml.
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SECTION VI
DEVELOPMENT OF MUSCLE MODEL
Body muscle accounts for approximately forty per cent of the
total body weight. During periods of high blood plasma glucose
concentration, body muscle converts glucose to glycogen in the intra-
cellular fluid where the glycogen is stored. During periods of
low blood plasma glucose concentration, the muscle glycogen is con-
verted to lactate and returned to the blood plasma to be converted
to glucose by the liver.
The rate at which glucose is converted to glycogen in the intra-
cellular fluid of the body muscle is a function of the insulin concen-
tration of the body muscle blood plasma. Insulin varies the glucose
admittance (GK23M) of the cell membrane separating the body muscle's
interstitial fluid (V2M) from its intracellular fluid (V3M) by -what
is known as an active transport system. The mathematical model




GK23M - is the glucose admittance of the cell membrane
(mg/min/mg/oil)
Vl, V2- are the total body blood plasma and interstitial
fluid volumes, respectively (ml)
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IC2M - is the insulin concentration of the body muscle
interstitial fluid (ng/ml).
The equation for (GK23M) has been derived from the data of R. C.
de Bodo, M.D., et al (16), (see Figures 14 and 15). The in vivo ca-
nine data of (16) relates the blood plasma glucose concentration, the
outflow of glucose to the tissue, and the inflow of glucose from the
liver, for different rates of insulin infusion into the blood of the
canine. By assuming that the basal inflow of glucose (145 mg/kg/hr,
3.8 gm/m²/hr) from the liver is entirely taken up by the central nervous
system (CNS) and that this CNS glucose requirement remains constant,
independent of the blood plasma glucose concentration, it is possible to
calculate both the glucose disappearance ratio (k, %/min), due to muscle
glucose absorption, and the average blood plasma insulin concentration
(ng/ml) for three different sets of conditions.
From the data of (16), it is possible to determine the rate at
which glucose is being absorbed by the muscle and also the average glu-
cose concentration over the time period of interest. It is also possible
to calculate the insulin concentration using input flow rates of insulin
and the overall body admittance of 285 (ng/min)/(ng/ml). From t = 0 to
t = 26 min of Figure 14, the average insulin concentration was calculated
to be 9.46 ng/ml while the glucose disappearance ratio was 4.6%/min.
Over the time interval t = 40 to t = 140 min of Figure 14, the insulin
concentration was calculated to be 6.8 ng/ml and the glucose disappear-
ance ratio ².2.1%/min. From Figure 15, for the time interval from t = 0
to t = 95 min, the insulin concentration was calculated to be 2.74 ng/ml












( INSULIN LOAD )
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FIGURE 15*
*In Vivo Test Data, de Bodo (16).
By plotting the near square law relationship between the glucose
disappearance ratio (k, %/min) and the insulin concentration (ng/ml),
and then using trial and error, it is possible to derive an equation
which describes the glucose disappearance ratio (k, %/min) as a
function of the insulin concentration (ng/ml).
(30)
To convert the glucose disappearance ratio (k, %/min) to glucose
admittance (GK23M) in terms of the insulin concentration (IC2M) of
the body muscle blood plasma, it is necessary to multiply the scaling
factor (0.533) by (2.38) and (k) by (Vl + V2)/100. The (2.38) factor
is required because the insulin concentration was calculated as average
overall body value while the insulin concentration (IC2M) of the body
muscle interstitial fluid compartment (V2M) is approximately one-half
of the calculated average value. The factor (VI + V2)/100 is required
because the disappearance ratio (k) was calculated as a (%/min) of the
total glucose contained in the overall body blood plasma and inter-
stitial fluid VI and V2.
k = (Glucose loss to muscle)/min 
(Glucose in V1 and V2) 	 x 100
or
(Glucose loss to muscle)/min = SEW3M =









represents the glucose admittance (GK23M) between the interstitial and
intracellular fluid of body muscle when the average body glucose con-
centration is approximately equal to the glucose concentration (GC2M)
of the interstitial fluid of the body muscle, and is substituted for
(Glucose Conc.) in equation (31) for (SEW3M). The mathematical model
for the rate at which glucose is converted to glycogen (SEW3M) in the
intracellular fluid (V3M) of the body muscle becomes:
The conversion of body muscle glycogen to lactate involves the
adrenal hormones adrenaline and glucocorticoids. This process is
relatively slow compared to action of both insulin and glucagon in
the regulation of the glucose concentration and for this reason
will not be modeled.
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SECTION VII
DEVELOPMENT OF COMPUTER MODEL 
The development of the computer model to describe the Dynamics
of the Glucose-Insulin-Glucagon System involves developing equations
to define all of the pertinent variables for each of the major body
components in terms of the particular body component's physical
characteristics and its inputs from the other major body components.
The resulting set of equations integrates all of the major body com-
ponents into the mathematical model.
In developing these equations, it was necessary to use mneumonic
terms for the many constants and variables that were both, compatible
with the Continuous Systems Modeling Program (CSMP) for the 360
Digital Computer, and would also have logical meaning so that anyone
of the many equations could be read without resorting to a glossary
for each term.
Development of Mneumonics 
The Continuous System Modeling Program (CSMP) requires that all
terms describing either constants or variables be defined by a string
of not more than six alpha-numeric characters and that the first
character be alphabetic. To meet this requirement and to also assign
meaning to the many constants and variables, a format was developed
which assigned meaning to each of the alpha-numeric characters and
its location in the six character alpha-numeric string, (see Table II






































































































































Table II are listed and defined in Table III. A brief explanation of
the significance of each of the six character positions of the
alpha-numeric terms follows:
Character Position (I) - Alpha -
The first character position will contain either the
letter "S" or a blank (no letter at all). The
letter "S" signifies that the term is a first
derivative. A blank signifies a non-derivative
term in which case one of the possible characters
of position (2) will be the first character of the
term.
Character Position (2) - Alpha -
Character Position (2) defines the substance that
is being labeled by the term. An example would be
"A" for glucagon (ng) or "G" for glucose (mg).
Character Position (3) - Alpha -
Character Position (3) assigns the type of dimension
which is applicable to the term. An example would
be "C" for concentration, where the glucagon con-
centration would be measured in (ng/ml) while the
glucose concentration would be (mg/ml).
Character Position (4, 5) - Numeric -
Character Position ( 4, 5) is used to define a loca-
tion in the major body component being modeled or
the place and direction of transport. A single
numeric "l, 2, or 3" defines the plasma, the
interstitial, or the intracellular fluids,
respectively. The double numeric "11" specifies
the input, while the "22" specifies the output.
All other double numerics are used to define the
place and direction of an admittance. The numeric
"12" would specify an admittance going from the
blood plasma into the interstitial fluid compart-
ment. The dimensions of admittance would be the
dimensions of Character Position (2) per unit of
concentration per minute. For insulin this would
be (ng/min)/(ng/ml)
Character Position (6) - Alpha -
This character position indicates the major body
component to which the term applies.
Character Position (7) - Alpha -
Character Position (7) will contain either the
letter "I" or be blank (no letter at all). The
letter "I" is used to indicate an initial condi-
tion. The absence of the letter "I" would make
one of the Character Position (5) characters the
last character of the term.
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Since no (CSMP) term can contain more than six alpha-numeric
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characters, it is obvious that either the first and/or the seventh
character positions must be blanks. The minimum number of alpha-
numeric characters making up a formated (CSMP) term is three. This
is the case when describing the blood plasma, interstitial, or intra-
cellular fluid volumes for any of the major body components. The
(CSMP) term for the interstitial fluid of the head would be (V2C).
Development of Equations 
To better understand how the equations which make up the mathem-
atical model for the Glucose-Insulin-Glucagon System have been
developed, the nine equations:
SGWIC = ((GCIS)*(BRllC) - (GClC)*(BR22C))*(HK) - (GClC
- GC2C)*(GKI2C)
GWIC = INTGRL(0.0, SGWIC)
GCIC = GCICI + GWIC/VlC
SGW2C = (GCIC - GC2C)*(GKl2C) - (GC2C - GC3C)*(GK23C)
GW2C = INTGRL(0.0, SGW2C)
GC2C = GC2CI + GW2C/V2C
SGW3C = (GC2C - GC3C)*(GK23C) - 23.0
GW3C = INTGRL(0.0, SGW3C)
GC3C = GC3CI + GW3C/V3C
VI
which describe the flow of glucose into, out of, and through the fluid
compartments of the head will be detailed. These nine equations are
divided into three groups with each group of three equations describ-
ing the glucose dynamics for the blood plasma compartment, the inter-
stitial fluid compartment, and the intracellular fluid compartments
of the head, respectively.
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The necessary constants are:
Volume:
VIC = 23.0 ml
V2C = 74.0 ml
V3C = 204.0 ml
Blood Flow Rate:
BRlIC = 322.0 ml/min
BR22C = 322.0 ml/min
Glucose Admittance:
GKl2C = 76.6 (mg/min)/(mg/ml)
GK23C = 38.3 (mg/min)/(mg/mI)
Initial Conditions:
GClCI = I.0 mg/ml
GC2CI = l.0 mg/ml
GC3CI = 1.0 mg/ml
Plasma Ratio:
HK = 0.727
The first group of three equations describes the glucose dynamics
in the blood plasma compartment (VlC) of the head (C). The first
equation in this group defines the rate (SGWlC) at which the weight
(W) of glucose is changing in the blood plasma compartment (VlC).
SGWlC = ((GCIS)*(BRIlC) 	 (GClC)*(BR22C))*(HK)
-(GCIC - GC2C)*(GKl2C)
The first factored term of this equation describes the transport
of glucose into and out of the head by the blood flow. The term
(GC1S) is the glucose concentration of the blood plasma compartment
(VlS) for the heart, and is used to define the glucose concentration
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of the blood entering the head. The plasma ratio (HK) is required
because the glucose concentration is defined as mg of glucose per
ml of plasma, while the blood flow into the head is for whole blood.
The second term of this equation describes the transport of glucose,
by perfusion, between the blood plasma and interstitial fluid com-
partments of the head in terms of the glucose concentration in each
of these compartments (GClC, GC2C) and the glucose admittance between
the compartments (GK12C). The admittance is assumed to be bidirec-
tional with (GK12C = GK2lC).
The second equation of the first group:
GWIC = INTGRL (0.0, SGWlC)
is a (CSMP) function block used to integrate the first equation
(SGWIC) to obtain the change of glucose weight (GW2C) in the blood
plasma compartment from time t = 0. The (0.0) term of this equation
sets the initial value of (GW1C) equal to (0.0).
The third equation of the first group:
GCIC = GC1CI + GW1C/V1C
describes the glucose concentration (GClC) in the blood plasma compart-
ment (V1C) of the head in terms of the initial glucose concentration
(GC1CI), the change of glucose weight (GW1C), and the blood plasma
volume (VlC) of the head.
The second group of three equations describes the glucose
dynamics in the interstitial fluid compartments (V2C) of the head.
The first of these three equations:
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SGW2C = (GC1C - GC2C)*(GK12C)
-(GC2C - GC3C)*(GK23C)
defines the rate (SGW2C) at which the weight of glucose in this com-
partment is changing. The first factored term of this equation des-
cribes the transport of glucose between the blood plasma and inter-
stitial fluid compartments in terms of the glucose concentrations
(GC2C, GC2C) in, and the glucose admittance between these compart-
ments. Similarly, the second factored term of this equation des-
cribes the transport of glucose between the interstitial fluid
compartment (V2C) and the intracellular fluid compartment (V3C).
The second and third equations of the second group:
GW2C = INTGRL(0.0, SGW2C)
GC2C = GC2CI + GW2C/V2C
are similar to the second and third equations of the first group,
defining the weight change of glucose (GW2C) and the glucose concentra-
tion (GC2C) in the interstitial fluid compartment (V2C) of the head.
The third group of three equations describes the glucose
dynamics in the intracellular fluid compartment (V3C) of the head.
This group is similar to the second group of equations with the
exception of the (23.0) term. 	 This term represents the glucose load
of (23.0) mg/min that is supplied to the brain to meet its glucose
requirements.
Similar equations have been written to define the dynamics of
both insulin and glucagon in the three fluid compartments (V1C, V2C,
V3C) of the head, and likewise for the other major body components.
SECTION VIII
RESULTS
The CSMP program to model the dynamics of the Glucose-Insulin
Glucagon System is listed in Figures 17a through 17e. The first
part of the program lists the constant and initial condition terms,
followed by the equations describing the dynamics for each of the
major body components. The last part of the program describes the
integration method, the time parameters, and the desired outputs and
the form for these outputs.
The CSMP model for the Dynamics of the Glucose-Insulin-Glucagon




3. 	 Insulin Load
Basal condition data was run for a period of 150 minutes first
with all initial conditions very nearly at basal level values (see
Figures 18a through 18f). To demonstrate the dynamic equilibrium of
the liver glycogen storage (EW3L), similar basal data was run but
with 'three different levels of initial glycogen stored in the liver
(EW3LI = 0.0, 10.0, and 19.25 gm), (see Figures 19a through 19c).
The model was then exercised with an almost instantaneous 8.5
gm glucose load in an attempt to duplicate the in vivo test data of
Finkelstein, et al (27), (see Figures 20a through 20d and 2Ia
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through 2If. The high initial body glucose concentrations, result-
ing from the glucose load, were brought back to the basal concentra-
tion levels by the many biological mechanisms of the body.
The third set of data was an attempt to duplicate the in vivo
test data of de Bodo, et al (16), (see Figures 14 and 15), by inject-
ing insulin into the system at different rates over an extended period
of time. The resulting excessively high body insulin concentrations
caused the body glucose concentration level to be depressed, (see
Figures 22a through 22c, and 23a through 23c). A description for
each of the three test conditions for the dynamic model of the
Glucose-Insulin-Glucagon System follows.
Basal Test 
Figures 18a through 18f show basal data for the major data points
of the Glucose-Insulin-Glucagon System model over a period of 150
minutes. The initial glycogen storage (EW3LI) for the liver was the
near equilibrium value of 16 gm. The (6.72 gm/min) rate of glucose
production from amino acid (GR22L2) is lower than the normal basal
level of (13.0 mg/min) due to the "Cori" cycle lactate glucose load
requirement of (6.25 mg/min) not being included in the Glucose-
Insulin-Glucagon System model. Had this glucose load been included,
the glucose concentration would have been reduced approximately 0.14
mg/ml, increasing the (GR22L2) output by approximately 7.0 gm/min to
the basal level of 13.0 gm/min due to the change in (GR22L2) with
respect to the change in glucose concentration being -47.8 (mg/min)/
(mg/ml).
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Figures 19a through 19c show the dynamic equilibrium for the
liver glycogen storage (EW3L) for initial glycogen storage (EW3LI)
levels of 0.0, 10.0, and 19.25 gm, respectively. This data demon-
strates the dynamic characteristic of the liver glycogen storage as
revealed in the data of Mortimore (49), (see Figure 12). For glycogen
storage (EW3L) levels (0.0, 10.0 gm), below the near equilibrium
value of 16 gm, glycogen was produced from glucose (SEW3L) at higher
rates (10.7, 5.8 mg/min, @ t = 27) than the rate at which glucose was
produced from glycogen (0.0, 0.0 mg/min, @ t = 27). The (SEW3L)
rate varied primarily as a function of the difference between the
equilibrium and the actual liver glycogen storage (EW3L). For the
condition where the actual liver glycogen storage (EW3L) level
(19.25 gm) was greater than the equilibrium glycogen storage level,
glucose was produced from glycogen (GR22Ll) at a much higher rate
(9.6 mg/min, @ t = 27) than was glycogen produced from glucose
(SEW3L) (l.8 mg/min, @ t = 27).
For the test runs of Figures 19a through 19c, a glucose load of
8.75 gm was also injected evenly into blood plasma volume (VlS) of
the left side of the heart during the period t = 28.45 to t = 29.95.
Over the following 120 minutes, approximately 5.3, 4.3, 2.6 gm of
glucose had been converted to glycogen by the liver for initial
glycogen storage (EW3LI) levels of 0.0, 10.0, and 19.25 gm, respective-
ly. Over the same period of time I.4, 1.7, and 2.3 gm of glucose
had been converted to glycogen in the muscle (EW3M) for initial liver
glycogen levels of 0.0, 10.0, and 19.25, respectively.
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Glucose Load Test 
A glucose load was applied to the Glucose-Insulin-Glucagon
System model so that the glucose dynamics test data obtained from
the model could be compared with the in vivo test data obtained by
Finkelstein, et al (27), (see Figures 20a through 20d), and the
validity of the model determined.
A glucose load of 8.75 gm was injected into the blood plasma
volume (VIS) of the left side of the heart during the period
t = 28.45 to t = 29.95 minutes. To simulate the glycogen stored in
the liver of a fasted canine, the initial liver glycogen storage
(EW3LI) level was set at 10.0 gm. To simulate the test conditions
of Finkelstein, the gastro-intestinal tract blood flow (BRIII,
BR22I) was reduced from 532 ml/min to 229 ml/min and where necessary
the blood flow was increased by approximately seventeen per cent to
maintain the cardiac output at 2187 ml/min.
The Glucose-Insulin-Glucagon System model test results are shown
in Figures 2Ia through 2lf. The initial blood glucose concentration
of approximately 3.5 mg/ml resulting from the glucose load of 8.75 gm,
decays almost exponentially (1— = 50 min) to the basal concentration
values of t = 27 over a 120 minute period. Approximately 4.2 gm of
glucose have been converted to glycogen (EW3L) by the liver.
The data of Finkelstein (see Figures 20a through 20d) indicates
a damped oscillatory type response to the glucose load for the glucose
concentrations, particularly in the arterial flow, while all the glucose
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concentration data for the Glucose-Insulin-Glucagon System model is
nearly exponential.
For the Glucose-Insulin-Glucagon model the peak pancreatic
insulin concentration output (IC22P), (see Figure 2ld), is 36 ng/ml
occurring approximately three minutes after the 8.75 gm glucose load,
while for the data of Finkelstein, (see Figure 20c), the peak pan-
creatic insulin output concentration is approximately 48 ng/ml, occurr-
ing approximately 30 minutes after the glucose load. The magnitude
of the insulin. concentrations throughout the body for both the model
and the in vivo test data are in close agreement, peaking at values
between 2.5 to 3.0 ng/ml. Where there is disagreement is the time
at which the peak insulin concentration occurs, usually being
approximately 30 minutes after the glucose load for the in vivo test
data of Finkelstein and 12 to 15 minutes for the Glucose-Insulin-
Glucagon System model. The arterial insulin concentration for the
in vivo test data of Finkelstein, (see Figure 20b), peaks at approx-
imately 15 minutes but has a magnitude of 3.5 ng/ml.
Insulin Load Test
The first insulin load test of the Glucose-Insulin-Glucagon
System model was performed to simulate the test data of de Bodo,
et al (16), (see Figure 14). An insulin load of 3900 ng/min was
injected into the blood plasma volume (VlS) of the left side of
the heart from t = 29.95 to t = 49.95, and then an insulin load of
1950 ng/min from t = 49.95 to t = 164.95. The response of the
Glucose-Insulin-Glucagon System model to this insulin load is shown in
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Figures 22a through 22c. There is good agreement between the in vivo
test data of de Bodo and the test data for the Glucose-Insulin-Gluca-
gon System model. The glucose concentration from t = 49.95 to
t = 164.95 for the model is between 0.35 and 0.45 mg/ml while the in
vivo test data has level of approximately 0.4 mg/ml. The falling and
rising transition times for the model are 35 and 95 minutes, respec-
tively, while for the in vivo data these transition times are 25 and
70 minutes. The waveshape for the muscle glucose concentration
(GCIM), (see Figure 22c), is of a damped oscillatory nature, resembling
the in vivo test data waveshape of de Bodo, (see Figure 14).
The liver glucose production at t = 140 increased by a factor of
almost three from a basal level of 16.3 mg/min to 43.1 mg/min. The
in vivo data showed an increase of approximately two.
The second insulin load test was an attempt to simulate the in
vivo test data of de Bodo, et al (16), (see Figure 15). An insulin
load of 778 ng/min was injected into the blood plasma volume (VlS)
of the left side of the heart in the Glucose-Insulin-Glucagon
System model from t 	 29.95 to t = 119.95 period. The response
for the glucose concentration level of the model is shown in Figures
23a through 23c. For the in vivo test data of de Bodo (see Figure
15), the glucose concentration changed at a rate of approximately
-5.0 x 10 -³ (mg/ml)/min during the period of time when insulin
was being injected into the canine, while for the Glucose-Insulin-
Glucagon System model the glucose concentration rate changed at a
- 3
rate of approximately-3.0 x 10 	 (mg/ml)/min.
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The recovery transition time back to basal glucose concentration
levels once the insulin load had been stopped was approximately 45
minutes for the Glucose-Insulin-Glucagon System model and 30 minutes
for the in vivo test data of de Bodo. The glucose concentration for
the in vivo test did not return to the original basal level but was
higher by approximately 0.05 mg/ml.
The liver glucose production throughout the period of the insulin
load (778 ng/min) remained constant for the Glucose-Insulin-Glucagon




CONCLUSIONS AND RECOMMENDATIONS 
The Basal Test results for the Glucose-Insulin-Glucagon System
model demonstrates the dynamic equilibrium that exists between the
level of glycogen stored (EW3L) in the liver, the glucose (GClL),
and insulin (ICIL) concentrations of the blood plasma perfusing the
liver. For the Glucose-Insulin-Glucagon System model the equili-
brium glycogen storate (EW3L) of the liver is approximately 16 gm,
as a result of a stable supply of glucose substrates from the many
body sources. Had the long term body functions involved in the
glucose dynamics also been modeled, as these glucose substrate
sources depleted with time, the blood plasma glucose and insulin
concentrations would also have diminished, causing the liver glycogen
storage equilibrium level to also be reduced.
For the Glucose Load Test the glucose concentration response
of the Glucose-Insulin-Glucagon System model to a 8.75 gm glucose load
was basically exponential back to the original basal glucose concen-
tration level of l.0 mg/ml, (see Figures 2Ia through 2If). The
response for the in vivo test data of Finkelstein, (see Figures
20a through 20d), for a glucose load was also exponential throughout
most of the canine with the exception for the data of the arterial
flow; here a damped oscillation was observed. The damped oscillation
for the arterial flow of the in vivo data is probably caused by
either the insulin caused, delayed modulation of the 23.0 mg/min
glucose load requirement of the head, or a glucose load requirement
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for the lungs modulated by a delayed insulin response. (This type
response has been observed for the muscle glucose concentration (GCIM)
for the Insulin Load Test, see Figure 22c.) For the Glucose-Insulin-
Glucagon System model, the 23.0 gm/min glucose load requirement for
the head remained nearly fixed for all levels of both glucose and
insulin concentration perfusing the head, while there was no glucose
requirement for the lungs other than the glucose needed to bring the
blood plasma (VlR) and the interstitial fluid (V2R) of the lungs into
equilibrium with the rest of the system.
A possible mode of action for the damped oscillatory response
of the arterial flow for the in vivo data, would be the delayed
response for the insulin. controlled active transport of glucose
into the intracellular fluid of either the head or the lungs
(V3C, V3R). An electrical analog is shown below of a non-linear
system which duplicates many of the characteristics of the active
transport glucose dynamics. The response of this electical analog
to a step input of glucose ( 	 s) is a damped oscillation, where the
magnitude of the first overshoot is controlled by the time constant
( 	 = C77.764_ ). The voltage Vs controls the glucose admittance
(Y23) between the interstitial fluid and the intracellular fluid. The
capacitor C I2 represents the sum of the blood plasma and interstitial
volumes.
One aspect of blood flow throughout the circulatory system that
has not been modeled is the Laminar flow through the arteries, cap-
illaries, and veins. The Laminar flow, together with the higher
concentration of red blood cells in the center of the flow (31),
would cause the blood concentrates to be distributed throughout the
body at a slower effective rate, and for the Laminar flow of blood
to exhibit the characteristics of a dynamic reservoir.
For the two tests in the Insulin Load Test there is generally
good agreement between the in vivo test data of de Bodo (see Figures
14 and 15), and the data from the Glucose-Insulin-Glucagon System
Model. Had the 6.25 mg/min lactate glucose load requirement (Cori
cycle) been included in the Glucose-Insulin-Glucagon System model,
the test data for the model would have been in closer agreement with
the in vivo test data.
The inclusion of the 6.25 mg/min lactate glucose load to the
liver glucose production would have meant a near two-fold increase
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in the liver glucose production (22.6 mg/min to 49.4 mg/min) between
the basal and 1950 ng/min insulin load periods, and lowered the
depressed glucose concentration level below 9.45 mg/ml, thus being in
closer agreement with the in vivo test data.
The inclusion of the 6.25 mg/min lactate glucose load requirement
would also have increased the rate (-3.0 x 10 - 3 (mg/mI)/min at
which the glucose concentration was changing due to the 778 ng/min
insulin load bringing this rate closer to the (-5.0 x 10 - 	 (mg/ml)/
min) rate for the in vivo test data. (The -3.0 x 10 - 3 (mg/ml/min)
figure is probably more of a result of the muscle model causing glucose
to be absorbed by the muscle at 0.27%/min rather than the 0.55%/min
that was calculated from the data of (16).)
The 6.25 mg/min lactate glucose load requirement will have little
effect on the transition response during the 3900 ng/min insulin load,
but will further degrade the recovery response by approximately 20%.
The fact that for the in vivo test data of de Bodo, (see Fig-
ures 14 and 15), the recovery, after removing the insulin load, of
the glucose concentration was to levels higher than the original
basal glucose concentration indicates that either new glucose sources
have been made available to the system or that the canine's glucose
load requirment has been reduced as a result of the high insulin
concentration, and that these insulin caused effects have not
recovered to their basal levels.
Major improvements to the Glucose-Insulin-Glucagon System model
could be made by incorporating into the model features that would
account for the damped oscillatory response observed in the in vivo
test data of Finkelstein, (see Figures 20a through 20d) for the
glucose concentration of the arterial blood flow, and also the
elevated glucose concentration for the arterial blood flow as com-
pared to the rest of the canine.
Modeling the adrenal and the effects that both adrenaline and
glucocorticoids have on the gluconeogenic substrates and the liver























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Non-Conforming Mneumonic Terms 
TERM 	 DESCRIPTION
A, B, C 	 Step functions used to generate INJECT timing . waveshape
AAN 	 Normalized amino acid concentration in the liver
AR 	 Rate of glucagon secretion from pancreas (ng/min)
BRIVC 	 Blood flow in inferior vena cava (ml/min)
E 	 Base of natural logarithm
EWM 	 Quantity of glycogen that has been produced from
glucose in the muscle
FACTOR 	 Factor of the variable (GR22LI) which is limited by
the function (GLGL)
GLGL 	 Limit function of the term (FACTOR)
GLOAD 	 Glucose load (mg/min)
GLUGLY 	 Limit function of the factored term (GLYSTO) for the
variable (SEW3L)
GLYSTO 	 Factor of variable (SEW3L) which is limited to pro-
duce (GLUGLY)
GRDELT 	 Net rate at which the glucose in the blood is chang-
ing (mg/min)
GRIN 	 Total rate at which glucose is being put into the
blood (mg/min)
GROUT 	 Total rate at which glucose is being removed from the
blood system (mg/min)
Table III (Continued)
Non-Conforming Mneumonic Terms 
TERM 	 DESCRIPTION
GRIC 	 Rate at which blood is transporting glucose into the
blood plasma volume (VlC) of the head.
GR22L1 	 Rate at which glycogen is converted to glucose by the
liver (mg/min)
GR22L2 	 Rate at which glucose is produced from amino acids by
the liver (mg/min)
GR22L3 	 Rate of glucose production from lactate in the liver
(mg/min)
GR22L4 	 Rate of glucose production from glycerol in the liver
(mg/min)
GW22Ll 	 Quantity of glucose produced from glycogen by the
liver (mg)
HEPART 	 Blood flow in hepatic artery
HK 	 Plasma ratio, ratio of blood plasma to whole blood,
_ 100 - Hematocrit 
100
ILOAD 	 Insulin load (ng/min)
INJECT 	 Timing waveshape used to control injection of etther
glucose or insulin into model
IR 	 Rate of insulin secretion from pancreas (ng/min)
LAR 	 Limit function for (AR) term
LIR 	 Limit function for (IR) term
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